| PCI 99-01 | ||
| EORTC 22003-08004 | ||
| EORTC 22993-08994 | ||
| RTOG 0212 | ||
| IG 00-96 | LD-SCLC: Hyperfraktioniert 2x 1,5Gy besser als 1x 1,8Gy | |
| IFCT 99-01 | ||
Target
Teil von
Schedule dependency of 21 day oral versus 3 day IV etoposide in combination with IV cisplatin in extensive stage small cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B study group.
J Clin Oncol 1995;13:1871-1879
2.) Niell HB, Herndon JE, Miller AA, et al.:
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.
J Clin Oncol 2005;23:3752-3759
3.) Noda K, Nishiwaki Y, Kawahara M, et al.:
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
N Engl J Med 2002;346:85-91
4.) Lara PN, Natale R, Crowley J, et al.:
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124.
J Clin Oncol 2009;27:2530-2535
5.) Hanna N, Bunn PA Jr, Langer C, et al.:
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
J Clin Oncol 2006;24:2038-2043
6.) Grønberg B H, et al.:
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial.
Lancet Oncol 2021; 22: 321–31
